We are live on
!
Find out more
B
Braidwell Portfolio holdings
AUM
$3B
1-Year Est. Return
46.72%
This Fund
S&P 500
This Quarter
Est. Return
-7.84%
1 Year Est. Return
+46.72%
3 Year Est. Return
+56.07%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.19B
AUM Growth
+$85M
(+2.7%)
Cap. Flow
-$861M
Cap. Flow
% of AUM
-27.01%
Top 10 Holdings %
Top 10 Hldgs %
36.68%
Holding
89
New
17
Increased
26
Reduced
11
Closed
10
Top Buys
| 1 |
CG Oncology
CGON
|
+$75.5M |
| 2 |
Spyre Therapeutics
SYRE
|
+$67.4M |
| 3 |
EXAS
Exact Sciences
EXAS
|
+$62.8M |
| 4 |
Inspire Medical Systems
INSP
|
+$52.6M |
| 5 |
Xenon Pharmaceuticals
XENE
|
+$50.1M |
Top Sells
| 1 |
Transmedics
TMDX
|
+$50.9M |
| 2 |
Vaxcyte
PCVX
|
+$27.5M |
| 3 |
Cullinan Oncology
CGEM
|
+$22.7M |
| 4 |
TRML
Tourmaline Bio
TRML
|
+$20.8M |
| 5 |
argenx
ARGX
|
+$20.2M |
Sector Composition
| 1 | Healthcare | 60.98% |
| 2 | Consumer Staples | 0.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Ironwood Pharmaceuticals
IRWD
$658M
| $28.9M | 0.91% |
4,438,232
+948,389
| +27% | +$6.71M |
|
|
27
Transmedics
TMDX
$2.61B
| $28.6M | 0.9% |
189,960
-424,571
| -69% | -$50.9M |
|
|
FNA
28
DELISTED
Paragon 28, Inc.
FNA
| $28.4M | 0.89% |
4,150,109
+784,500
| +23% | +$6.63M |
|
29
Immunocore
IMCR
$1.76B
| $27M | 0.85% |
+797,268
| New | +$40.7M |
|
|
AKRO
30
DELISTED
Akero Therapeutics
AKRO
| $25.4M | 0.8% |
+1,084,400
| New | +$23.2M |
|
|
APLS
31
DELISTED
Apellis Pharmaceuticals
APLS
| $23.5M | 0.74% |
+611,800
| New | +$27.7M |
|
32
Alphatec Holdings
ATEC
$1.39B
| $22.9M | 0.72% |
+2,194,900
| New | +$25.6M |
|
33
Lexeo Therapeutics
LXEO
$372M
| $22.2M | 0.7% |
1,382,481
+60,204
| +5% | +$874K |
|
34
Krystal Biotech
KRYS
$10.3B
| $19.7M | 0.62% |
107,179
-69,910
| -39% | -$11.7M |
|
35
Relay Therapeutics
RLAY
$4.25B
| $19.6M | 0.62% |
3,006,799
-737,200
| -20% | -$5.04M |
|
|
NVRO
36
DELISTED
NEVRO CORP.
NVRO
| $14.3M | 0.45% |
1,698,768
-77,600
| -4% | -$827K |
|
37
Lexicon Pharmaceuticals
LXRX
$977M
| $13.9M | 0.44% |
+8,294,950
| New | +$14.9M |
|
38
Arvinas
ARVN
$534M
| $13.8M | 0.43% |
+517,230
| New | +$16.5M |
|
39
Sarepta Therapeutics
SRPT
$1.86B
| $12.9M | 0.41% |
+81,900
| New | +$10.5M |
|
40
Iovance Biotherapeutics
IOVA
$2.12B
| $11.8M | 0.37% |
1,466,610
+806,588
| +122% | +$8.64M |
|
41
Ocular Therapeutix
OCUL
$2.18B
| $11.2M | 0.35% |
+1,643,770
| New | +$10.1M |
|
42
Alector
ALEC
$167M
| $10.8M | 0.34% |
2,380,704
| – | – |
|
43
SkinHealth Systems
SKIN
$117M
| $9.83M | 0.31% |
+5,120,685
| New | +$14.4M |
|
44
LivaNova
LIVN
$4.36B
| $9.53M | 0.3% |
+173,900
| New | +$9.91M |
|
45
Dianthus Therapeutics
DNTH
$5.46B
| $9.49M | 0.3% |
+366,851
| New | +$8.82M |
|
46
Replimune Group
REPL
$813M
| $9.12M | 0.29% |
+1,013,377
| New | +$7.06M |
|
47
Castle Biosciences
CSTL
$729M
| $9.06M | 0.28% |
+416,100
| New | +$9.27M |
|
48
BridgeBio Pharma
BBIO
$16.2B
| $8.75M | 0.27% |
345,571
+744
| +0.2% | +$20.3K |
|
49
Celcuity
CELC
$4.46B
| $8.46M | 0.27% |
+516,643
| New | +$8.64M |
|
50
4D Molecular Therapeutics
FDMT
$611M
| $7.75M | 0.24% |
369,458
-683,027
| -65% | -$17.1M |
|
Similar funds
NC
VVP
SP
DIG
ECP
PCM
ROTUOC
SM